BSE SME पर ₹118 में हिमालय न्यूट्रावेडिक्स इंडिया के शेयर 11.32% प्रीमियम पर लिस्ट

हिमालय न्यूट्रावेडिक्स इंडिया के शेयरों ने 29 सितंबर, 2026 को BSE SME प्लेटफॉर्म पर ₹118 प्रति शेयर पर लिस्ट किया, जबकि IPO इश्यू प्राइस ₹106 प्रति शेयर थी. लिस्टिंग प्राइस, इश्यू प्राइस पर 11.32% प्रीमियम दर्शाता है.

लिस्टिंग के बाद, स्टॉक ₹122.50 पर ट्रेड किया गया, इश्यू प्राइस से 15.57% और लिस्टिंग प्राइस से 3.81% तक. During the session, Himalaya Nutravedics India shares touched a high of ₹123.90 and a low of ₹118, with around 7 lakh shares changing hands on the BSE at the 11:16 AM snapshot.

लिस्टिंग कंपनी के IPO के बाद हुई, जो 22 सितंबर से 24 सितंबर, 2026 तक सब्सक्रिप्शन के लिए खुली थी. The ₹26.50 crore book-built SME issue was subscribed 2.24 times overall. IPO का प्राइस बैंड ₹100 से ₹106 प्रति शेयर तय किया गया है.

Himalaya Nutravedics India manufactures, markets and distributes Ayurvedic and nutraceutical formulations. It also undertakes third-party contract manufacturing and produces formulations including softgel and hardgel capsules, tablets, liquid orals and medicated oils. 

Himalaya Nutravedics India IPO Listing Details

Himalaya Nutravedics India IPO was a ₹26.50 crore book-built SME issue comprising 24,99,600 equity shares and was entirely a fresh issue. The issue included a market-maker reservation of 1,26,000 shares. 

IPO 22 सितंबर को खुला और 24 सितंबर, 2026 को बंद. Its price band was ₹100 to ₹106 per share and the final issue price was ₹106. The IPO was subscribed 2.24 times overall, with QIB subscription at 1 time, NII at 2.90 times and Individual Investors at 2.56 times.

The company also raised ₹7.53 crore from anchor investors through the allotment of 7,10,400 shares at ₹106 per share on September 21. 

Himalaya Nutravedics India listed at ₹118 on BSE SME and subsequently traded at ₹122.50 at the reported morning snapshot.

- जारी करने की कीमत: ₹106 प्रति शेयर
- BSE SME लिस्टिंग की कीमत: ₹118 प्रति शेयर
- Listing Premium: 11.32%
- ट्रेडिंग की कीमत: ₹122.50 प्रति शेयर
- Change From Issue Price: +15.57%
- इंट्राडे हाई: ₹123.90
- इंट्राडे लो: ₹118
- कुल सब्सक्रिप्शन: 2.24 बार
- फ्रेश इश्यू: ₹26.50 करोड़
- बिक्री के लिए ऑफर: शून्य
- प्राइस बैंड : ₹100 से ₹106 प्रति शेयर
- IPO खोलने की तिथि: 22 सितंबर, 2026
- IPO बंद होने की तिथि: 24 सितंबर, 2026
- लिस्टिंग की तिथि: 29 सितंबर, 2026
- एक्सचेंज: BSE SME

फर्स्ट-डे ट्रेडिंग परफॉर्मेंस

Listing Price: Himalaya Nutravedics India listed at ₹118 per share, ₹12 above its ₹106 issue price. This represented an 11.32% listing premium. 

Post-listing price: At the 11:16 AM snapshot, the shares traded at ₹122.50, representing a 15.57% premium over the IPO issue price and a 3.81% increase from the listing price. 

Intraday high: The stock touched ₹123.90, approximately 16.89% above the ₹106 issue price.

Intraday low: The shares touched a low of ₹118, the same as the listing price and 11.32% above the issue price. 

वॉल्यूमः रिपोर्ट किए गए मार्केट स्नैपशॉट पर BSE पर लगभग 7 लाख शेयरों ने हाथ बदल दिए थे.

Subscription context: The IPO was subscribed 2.24 times overall. NII subscription stood at 2.90 times, Individual Investors at 2.56 times and QIB subscription at 1 time. 

ग्रोथ ड्राइवर और चुनौतियां

ग्रोथ ड्राइवर

Product Portfolio: Himalaya Nutravedics India manufactures Ayurvedic and nutraceutical products across dosage forms including softgel and hardgel capsules, tablets, liquid orals and medicated oils.

Contract Manufacturing: Alongside its own manufacturing, marketing and distribution activities, the company undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical businesses. 

Business Expansion: The company plans to allocate IPO proceeds towards branding, digital marketing and sales expansion, providing capital for broader business development.

Financial Growth: Total income increased to ₹43.12 crore in FY26 from ₹21 crore in FY25, while profit after tax increased to ₹7.39 crore from ₹2.23 crore. EBITDA increased to ₹8.10 crore from ₹2.99 crore.

चुनौतियां

Working Capital Requirements: The company has identified working capital as a significant funding requirement and plans to allocate ₹13.75 crore of net IPO proceeds towards this purpose. 

Regulatory Exposure: Ayurvedic and nutraceutical products operate within regulatory frameworks governing manufacturing, product standards, labelling and marketing.

Brand-Building Execution: The company plans significant expenditure on business development and digital marketing, making effective deployment of these funds relevant to its expansion strategy.

Competitive Market: The Ayurvedic, wellness and nutraceutical markets include established brands as well as emerging manufacturers and contract manufacturing companies.

SME Scale: As an SME-listed company with a relatively smaller operating base, business performance can be more sensitive to changes in customer demand and working-capital requirements.

IPO आय का उपयोग

Himalaya Nutravedics India's ₹26.50 crore IPO was entirely a fresh issue. There was no offer-for-sale component, meaning the proceeds from the fresh issue are intended for the company's stated corporate requirements. 

The company plans to use ₹13.75 crore from the net proceeds for working capital requirements and another ₹7.50 crore for business development and digital marketing activities. शेष आय का उद्देश्य सामान्य कॉर्पोरेट उद्देश्यों के लिए है.

मुख्य उपयोग में शामिल हैं:
- ₹13.75 crore towards funding working capital requirements.
- ₹7.50 crore towards business development and digital marketing activities.
- Remaining proceeds towards general corporate purposes. 

Following the IPO, promoter and promoter group shareholding stood at 68.13%, compared with 95.14% before the issue. 

बिज़नेस और IPO ओवरव्यू

Himalaya Nutravedics India is engaged in manufacturing, marketing and distributing Ayurvedic and nutraceutical formulations in India. The company also provides third-party contract manufacturing services to other Ayurvedic and nutraceutical companies. 

Its portfolio includes formulations across several dosage forms, including softgel capsules, hardgel capsules, tablets, liquid orals and medicated oils covering multiple wellness and therapeutic segments. बिज़नेस स्टैंडर्ड
31 जुलाई, 2026 तक, कंपनी के 86 कर्मचारी थे. For FY26, total income stood at ₹43.12 crore, compared with ₹21 crore in FY25. टैक्स के बाद लाभ ₹2.23 करोड़ से बढ़कर ₹7.39 करोड़ हो गया, जबकि EBITDA ₹2.99 करोड़ से बढ़कर ₹8.10 करोड़ हो गया.

The ₹26.50 crore IPO comprised an entirely fresh issue of 24,99,600 shares. The price band was ₹100 to ₹106 per share, and the IPO was open for subscription from September 22 to September 24. The issue received 2.24 times overall subscription.

Himalaya Nutravedics India listed on BSE SME at ₹118 on September 29, an 11.32% premium to the ₹106 issue price. At the 11:16 AM market snapshot, the stock traded at ₹122.50 after reaching an intraday high of ₹123.90 and a low of ₹118, with around 7 lakh shares changing hands.